An Open Clinical Trial of Cortexin in Cerebral Ischemia

Машин, В В; Belova, L. A.; Chaplanova, O. I.; Khusnullina, A F; Manasyan, Albert

doi:10.1007/s11055-016-0247-4

Cited by 6 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These elements of cortexin have specific target ranges to modulate several molecular and cellular steps of the pathologic process [28] . In a clinical study investigating cortexin, patients with brain ischemia showed favorable outcomes such as a decrease or complete regression in focal neurological symptoms, positive alterations in the markers of cognitive impairment, mood normalization, and decreased levels of depression after cortexin therapy [29] . In a study investigating the effects of cortexin on the recovery of traumatic peripheral facial nerve paralysis models experimentally induced in rabbits by conserving nerve integrity, favorable effects were observed on neural fibrotic degeneration, axonal degeneration, normal myelin construction, and edema in cortexin group compared to the control group [30] .…”

Section: Discussionmentioning

confidence: 99%

The Protective Effect of Cortexin on Cisplatin-Induced Ototoxicity

et al. 2018

View full text Add to dashboard Cite

OBJECTIVE:The aim of this report is to evaluate whether cortexin provides any protective activity against ototoxicity of cisplatin. MATERIALS and METHODS:The study was performed on 30 healthy adult Wistar Albino rats, and rats were randomly divided into three groups of ten. Group I (Control group) was given intraperitoneal (ip) saline solution 1 mL/day. Group II (Cisplatin group) was given ip cisplatin for 2 days at doses of 10 mg/kg. Group III (Cisplatin + Cortexin group) was given ip cisplatin for 2 days at same doses with ip cortexin 2 mg/day for 7 days. Before and on the fourth day of the study, all subjects underwent auditory brainstem response (ABR) and distortion product otoacoustic emissions (DPOAE) tests. At the end of fourth day, half of the subjects in all three groups were decapitated, and their cochlea were removed for histopathologic examination. On the eighth day, tests of the remaining subjects and histopathological examinations were repeated. RESULTS:ABR tests on the fourth and eighth days showed elevations in the mean hearing thresholds of Groups II and III compared to Group I (p<0.05). DPOAE tests revealed a loss in emission values on the fourth and eighth days of the study compared to the baseline in Groups II and III.Comparison of Groups II with III showed that emission loss was higher in Group II at both time points, and the difference was more pronounced on the eighth day. Histopathological findings supported these tests. CONCLUSION:Cortexin provide protective activity against cisplatin-induced ototoxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

The Protective Effect of Cortexin on Cisplatin-Induced Ototoxicity

et al. 2018

View full text Add to dashboard Cite

show abstract

“…В настоящее время для лечения ИИ эф-фективно используются препараты пептидной структуры, сочетающие ноотропный, вазоактивный, нейропротек-тивный эффекты. Одним из пептидных нейропротекто-ров, широко применяемых при различных неврологиче-ских заболеваниях, в том числе в остром и раннем восста-новительном периодах ИИ, является препарат кортексин [12][13][14].…”

Section: лечение нервных и психических заболеванийunclassified

Efficacy of cortexin in acute and recovery periodes of hemispheric ischemic stroke

Belova

Машин

Abramova

et al. 2016

Z. nevrol. psikhiatr. im. S.S. Korsakova

Self Cite

View full text Add to dashboard Cite

“…В процессе терапии препаратом кортексин дисциркуляторной энцефалопатии, развившейся на фоне артериальной гипертензии (АГ) и/или атеросклероза, уменьшилась или полностью регрессировала негрубая очаговая неврологическая симптоматика. В ходе лечения препаратом кортексин произошли положительные изменения показателей когнитивных нарушений, которые либо полностью восстановились, либо сохранились на уровне «легкие когнитивные нарушения», нормализовалось психоэмоциональное состояние пациентов, уменьшился уровень депрессии [13,14].…”

unclassified